FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068862334> ?p ?o ?g. }

• W2068862334 endingPage "543" @default.
• W2068862334 startingPage "530" @default.
• W2068862334 abstract "Objectives.— The primary objective was to compare the efficacy of a sumatriptan and naproxen combination medication (SumaRT/Nap—85 mg sumatriptan and 500 mg naproxen sodium), a butalbital-containing combination medication (BCM—50 mg butalbital, 325 mg acetaminophen, 40 mg caffeine), and placebo when used to treat moderate to severe migraine headache pain in subjects who used BCMs in the past. Background.— Despite the lack of Food and Drug Administration approval and the absence of placebo-controlled trials to demonstrate efficacy, butalbital-containing medications are among the most commonly prescribed acute migraine treatments in the United States. Butalbital-containing medications are associated with serious and undesirable side effects, and have been linked to the chronification of migraine and development of medication-overuse headaches. This study compares the relative efficacy, safety, and tolerability of a fixed dose SumaRT/Nap versus a BCM and placebo. Methods.— Enrolled subjects were required to have treated at least 1 migraine with a butalbital medication in the past. Enrolled subjects treated 3 moderate to severe migraines using each of the 3 study treatments once in a randomized sequence. The primary endpoint compared SumaRT/Nap versus BCM for sustained pain freedom at 2-24 hours without the use of any rescue medication. This study combines data from 2 identical outpatient, randomized, multicenter, double-blind, double-dummy, 3 attack crossover studies in adult migraineurs (International Classification of Headache Disorders, 2nd edition). Results.— A total of 442 subjects treated at least 1 attack with study medication. The majority of the treated subjects were female (88%) with a mean age 43 years, who reported that their migraines had a severe impact on their lives (78% with Headache Impact Test-6 of >59). At screening, 88% of subjects reported current butalbital use; 68% had used butalbital for more than 6 weeks; and 82% reported satisfaction with butalbital. Across treatment groups, 28-29% of subjects took study medication within 15 minutes of migraine onset, 34-37% of subjects took study medication >15 minutes to 2 hours after onset, and 32-36% of subjects took study medication more than 2 hours after onset. This study did not detect a difference at the nominal 0.05 level in percent sustained pain-free between SumaRT/Nap (8%), BCM (6%), and placebo (3%). SumaRT/Nap was superior to BCM for pain free at 2, 4, 6, 8, 24, 48 hours (P ≤ .044); pain relief (mild or no pain) at 2, 4, 6, 8, 24, 48 hours (P ≤ .01); sustained pain relief 2-24 hours (P < .001); migraine free (pain free with no nausea, photophobia, or phonophobia) at 4, 6, 8, 24, 48 hours (P ≤ .046); and complete symptom free (migraine free with no neck/sinus pain) at 4, 6, 8, 48 hours (P ≤ .031). Adverse event incidence was similar for all treatments (10%, 12%, and 9% for placebo, SumaRT/Nap, and BCM, respectively). Nausea was the most frequent adverse event (2%, 2%, and <1% for placebo, SumaRT/Nap, and BCM, respectively). Five serious adverse events were reported by 3 subjects: viral meningitis and colon neoplasm (placebo); chest pain and hypertension 17 days postdose (SumaRT/Nap); and breast cancer (BCM). Investigators judged no serious adverse events related to study medication. Conclusions.— This study primarily included subjects whose migraines significantly impacted their lives. Before the study, these subjects used butalbital-containing medications as part of their current migraine treatment regimen and were satisfied with it, suggesting they were butalbital responders who had found a workable treatment strategy for themselves. When treated with SumaRT/Nap versus BCM in this study, however, a significant proportion of subjects reported better treatment outcomes for themselves for both migraine pain and associated symptoms. Use of SumaRT/Nap was also associated with less rescue medication use and a longer time before use of rescue medication compared with both BCM and placebo." @default.
• W2068862334 created "2016-06-24" @default.
• W2068862334 creator A5010255066 @default.
• W2068862334 creator A5023730853 @default.
• W2068862334 creator A5027687514 @default.
• W2068862334 creator A5035437507 @default.
• W2068862334 creator A5084396069 @default.
• W2068862334 creator A5087172990 @default.
• W2068862334 creator A5090593808 @default.
• W2068862334 date "2011-11-21" @default.
• W2068862334 modified "2023-09-27" @default.
• W2068862334 title "Sumatriptan-Naproxen and Butalbital: A Double-Blind, Placebo-Controlled Crossover Study" @default.
• W2068862334 cites W1972241691 @default.
• W2068862334 cites W2037737308 @default.
• W2068862334 cites W2041898141 @default.
• W2068862334 cites W2060416301 @default.
• W2068862334 cites W2079083206 @default.
• W2068862334 cites W2083727172 @default.
• W2068862334 cites W2086126627 @default.
• W2068862334 cites W2111548432 @default.
• W2068862334 cites W2121750957 @default.
• W2068862334 cites W2135331807 @default.
• W2068862334 cites W2141517709 @default.
• W2068862334 cites W2164727670 @default.
• W2068862334 cites W2166530830 @default.
• W2068862334 doi "https://doi.org/10.1111/j.1526-4610.2011.02039.x" @default.
• W2068862334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22103635" @default.
• W2068862334 hasPublicationYear "2011" @default.
• W2068862334 type Work @default.
• W2068862334 sameAs 2068862334 @default.
• W2068862334 citedByCount "20" @default.
• W2068862334 countsByYear W20688623342012 @default.
• W2068862334 countsByYear W20688623342013 @default.
• W2068862334 countsByYear W20688623342014 @default.
• W2068862334 countsByYear W20688623342015 @default.
• W2068862334 countsByYear W20688623342016 @default.
• W2068862334 countsByYear W20688623342017 @default.
• W2068862334 countsByYear W20688623342018 @default.
• W2068862334 countsByYear W20688623342022 @default.
• W2068862334 crossrefType "journal-article" @default.
• W2068862334 hasAuthorship W2068862334A5010255066 @default.
• W2068862334 hasAuthorship W2068862334A5023730853 @default.
• W2068862334 hasAuthorship W2068862334A5027687514 @default.
• W2068862334 hasAuthorship W2068862334A5035437507 @default.
• W2068862334 hasAuthorship W2068862334A5084396069 @default.
• W2068862334 hasAuthorship W2068862334A5087172990 @default.
• W2068862334 hasAuthorship W2068862334A5090593808 @default.
• W2068862334 hasConcept C107513589 @default.
• W2068862334 hasConcept C126322002 @default.
• W2068862334 hasConcept C141071460 @default.
• W2068862334 hasConcept C142724271 @default.
• W2068862334 hasConcept C169760540 @default.
• W2068862334 hasConcept C170493617 @default.
• W2068862334 hasConcept C197934379 @default.
• W2068862334 hasConcept C204787440 @default.
• W2068862334 hasConcept C27081682 @default.
• W2068862334 hasConcept C2778115740 @default.
• W2068862334 hasConcept C2778375690 @default.
• W2068862334 hasConcept C2778541695 @default.
• W2068862334 hasConcept C2778871607 @default.
• W2068862334 hasConcept C2778938600 @default.
• W2068862334 hasConcept C2780966972 @default.
• W2068862334 hasConcept C2909752691 @default.
• W2068862334 hasConcept C42219234 @default.
• W2068862334 hasConcept C71924100 @default.
• W2068862334 hasConcept C86803240 @default.
• W2068862334 hasConcept C87813604 @default.
• W2068862334 hasConceptScore W2068862334C107513589 @default.
• W2068862334 hasConceptScore W2068862334C126322002 @default.
• W2068862334 hasConceptScore W2068862334C141071460 @default.
• W2068862334 hasConceptScore W2068862334C142724271 @default.
• W2068862334 hasConceptScore W2068862334C169760540 @default.
• W2068862334 hasConceptScore W2068862334C170493617 @default.
• W2068862334 hasConceptScore W2068862334C197934379 @default.
• W2068862334 hasConceptScore W2068862334C204787440 @default.
• W2068862334 hasConceptScore W2068862334C27081682 @default.
• W2068862334 hasConceptScore W2068862334C2778115740 @default.
• W2068862334 hasConceptScore W2068862334C2778375690 @default.
• W2068862334 hasConceptScore W2068862334C2778541695 @default.
• W2068862334 hasConceptScore W2068862334C2778871607 @default.
• W2068862334 hasConceptScore W2068862334C2778938600 @default.
• W2068862334 hasConceptScore W2068862334C2780966972 @default.
• W2068862334 hasConceptScore W2068862334C2909752691 @default.
• W2068862334 hasConceptScore W2068862334C42219234 @default.
• W2068862334 hasConceptScore W2068862334C71924100 @default.
• W2068862334 hasConceptScore W2068862334C86803240 @default.
• W2068862334 hasConceptScore W2068862334C87813604 @default.
• W2068862334 hasIssue "4" @default.
• W2068862334 hasLocation W20688623341 @default.
• W2068862334 hasLocation W20688623342 @default.
• W2068862334 hasOpenAccess W2068862334 @default.
• W2068862334 hasPrimaryLocation W20688623341 @default.
• W2068862334 hasRelatedWork W1591155495 @default.
• W2068862334 hasRelatedWork W1994172792 @default.
• W2068862334 hasRelatedWork W2007237080 @default.
• W2068862334 hasRelatedWork W2020900211 @default.
• W2068862334 hasRelatedWork W2022556905 @default.
• W2068862334 hasRelatedWork W2033450638 @default.

• next